COMPANY OVERVIEW
Mimetas, headquartered in Leiden, Netherlands (Europe's biotech hub), developed the OrganoPlate platform—a 384-well plate format organ-on-chip system enabling high-throughput screening. Founded in 2013 as a Leiden University spin-off, their 3-lane microfluidic design creates perfused tubular structures ideal for kidney, gut, blood vessel, and tumor modeling at pharmaceutical screening scale.
ORGANOPLATE TECHNOLOGY
- 3-Lane Design: Gel lane, perfusion channel, and medium reservoir in each microfluidic unit
- 384-Well Format: Standard SBS plate compatibility for automated liquid handling and HCS imaging
- Gravity-Driven Flow: Rocker-based perfusion eliminates external pumps
- 40-96 Models/Plate: High-throughput screening capacity for compound libraries
- PhaseGuide Technology: Capillary pressure barriers enabling precise gel patterning
KEY APPLICATIONS
- Kidney proximal tubule nephrotoxicity screening (validated with >100 compounds)
- Gut barrier permeability and inflammatory bowel disease modeling
- Blood-brain barrier penetration studies
- Tumor microenvironment and immuno-oncology applications
- Vascular models for angiogenesis and thrombosis
PHARMA ADOPTION
Mimetas systems are deployed at 15+ major pharmaceutical companies including Janssen, Galapagos, and Boehringer Ingelheim. Their high-throughput format bridges the gap between traditional 2D screening and complex organ-on-chip models, enabling routine use in drug discovery pipelines.